Reports Q4 revenue $26.59M, consensus $24.79M. “2025 marked an important execution year for NeuroPace (NPCE), with strong growth and significant improvement toward cash flow break-even, increasing focus on our core RNS business, and meaningful progress across our strategic priorities,” said Joel Becker, Chief Executive Officer of NeuroPace. “Looking ahead, we believe 2026 has the potential to be a transformational year for the Company, as we build on commercial momentum, prepare for indication expansion, and launch as well as advance new products that expand the reach and impact of personalized neuromodulation.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NPCE:
- NPCE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NeuroPace price target raised to $19 from $18 at H.C. Wainwright
- Morning Movers: L3Harris Technologies jumps after DoW investment
- NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M
- NeuroPace sees Q1 revenue $21M-$22M, consensus $22.35M